With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne® is Fresenius ...

LAKE ZURICH, Ill., April 09, 2026--(BUSINESS WIRE)--Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for ...

Patients treated with TYENNE ® (tocilizumab-aazg) are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive ...

The SC formulation is now available in a prefilled syringe and an autoinjector. Tyenne ® (tocilizumab-aazg), a biosimilar to Actemra ® (tocilizumab), is now available in a subcutaneous (SC) ...

Fresenius Kabi has issued a recall of Tyenne (tocilizumab-aazg) injection in 20 ml vials following an internal company investigation, which found the product contained glass particles. The recall ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne ® (tocilizumab-aazg), in a ...

Fresenius Kabi, a part of Fresenius, and a leading provider of essential medicines and medical technologies, announced today that the Centers for Medicare & Medicaid Services has issued ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific ...

Tyenne® (tocilizumab-aazg), a biosimilar to Actemra ® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced ...